BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34724407.
- Also identified by DOI 10.7326/ACPJ202111160-123.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Borobia AM, Carcas AJ, Perez-Olmeda M, et al. <b>Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.</b> Lancet. 2021;398:121-30. 34181880.
Medical subject headings
- COVID-19
- Vaccines